Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 100,066	$ 49,271
General and administrative	30,647	14,198
Total operating expenses	130,713	63,469
Loss from operations	(130,713)	(63,469)
Interest and other income, net	390	57
Net loss	(130,323)	(63,412)
Accretion on redeemable convertible preferred stock		(705)
Deemed dividend – beneficial conversion feature on redeemable convertible preferred stock		(6,219)
Net loss attributable to common stockholders	$ (130,323)	$ (70,336)
Net loss per share attributable to common stockholders, basic and diluted	$ (3.40)	$ (4.15)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	38,316,273	16,962,398